205 related articles for article (PubMed ID: 23378579)
1. The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.
Asrani K; Keri RA; Galisteo R; Brown SA; Morgan SJ; Ghosh A; Tran NL; Winkles JA
Mol Cancer Res; 2013 Apr; 11(4):393-404. PubMed ID: 23378579
[TBL] [Abstract][Full Text] [Related]
2. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
Kim S; Han J; Shin I; Kil WH; Lee JE; Nam SJ
Exp Mol Med; 2012 Aug; 44(8):473-82. PubMed ID: 22627808
[TBL] [Abstract][Full Text] [Related]
3. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
Momeny M; Saunus JM; Marturana F; McCart Reed AE; Black D; Sala G; Iacobelli S; Holland JD; Yu D; Da Silva L; Simpson PT; Khanna KK; Chenevix-Trench G; Lakhani SR
Oncotarget; 2015 Feb; 6(6):3932-46. PubMed ID: 25668816
[TBL] [Abstract][Full Text] [Related]
4. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity.
Willis AL; Tran NL; Chatigny JM; Charlton N; Vu H; Brown SA; Black MA; McDonough WS; Fortin SP; Niska JR; Winkles JA; Cunliffe HE
Mol Cancer Res; 2008 May; 6(5):725-34. PubMed ID: 18505918
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells.
Tang FY; Chiang EP; Sun YC
J Nutr Biochem; 2008 May; 19(5):287-94. PubMed ID: 17651959
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
7. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
[TBL] [Abstract][Full Text] [Related]
8. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.
Aceto N; Duss S; MacDonald G; Meyer DS; Roloff TC; Hynes NE; Bentires-Alj M
Breast Cancer Res; 2012 Oct; 14(5):R131. PubMed ID: 23062209
[TBL] [Abstract][Full Text] [Related]
10. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
[TBL] [Abstract][Full Text] [Related]
11. HRG-β1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells.
Kim J; Jeong H; Lee Y; Kim C; Kim H; Kim A
BMC Cancer; 2013 Aug; 13():383. PubMed ID: 23937725
[TBL] [Abstract][Full Text] [Related]
12. Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells.
Yamashita N; Saito N; Zhao S; Terai K; Hiruta N; Park Y; Bujo H; Nemoto K; Kanno Y
Exp Cell Res; 2018 May; 366(1):34-40. PubMed ID: 29501698
[TBL] [Abstract][Full Text] [Related]
13. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
[TBL] [Abstract][Full Text] [Related]
15. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.
Ruan SQ; Wang ZH; Wang SW; Fu ZX; Xu KL; Li DB; Zhang SZ
Biochem Biophys Res Commun; 2012 Apr; 420(2):385-90. PubMed ID: 22425775
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
17. Heregulin controls ERα and HER2 signaling in mammospheres of ERα-positive breast cancer cells and interferes with the efficacy of molecular targeted therapy.
Fukui F; Hayashi SI; Yamaguchi Y
J Steroid Biochem Mol Biol; 2020 Jul; 201():105698. PubMed ID: 32404282
[TBL] [Abstract][Full Text] [Related]
18. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
Shi X; Xu L; Yu J; Fang X
Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
[TBL] [Abstract][Full Text] [Related]
19. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
20. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]